Translational Research

Director, Pharmacology (in vivo) (GB21-288)

Reporting to the CSO, the Director, Pharmacology (in vivo) will oversee translation research teams to execute in vivo studies, executed in-house or through CROs.

About Catalyst Biosciences, the Protease Medicines company

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a pre-clinical C3-degrader program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.

Key responsibilities

  • Conceptualize, design, and guide the execution of in vivo studies performed both internally and externally.
  • Provide strategic and scientific leadership as it relates to pharmacology efforts to advance projects as required.
  • Plan, resource and prioritize in-house and outsourced pharmacology activities.
  • Manage, mentor and guide team of scientists.

**Title/Level will commensurate with years of experience and education


  • PhD plus 8 years plus of combined years of postdoctoral research experience and/or in vivo experience in biotech and/or pharma industry.
  • Experience working with external service providers.
  • Experiencing writing detailed in vivo protocols.
  • Experience directing the work of in vivo scientists.
  • Outstanding communication and interpersonal skills.

Thank you for your interest in Catalyst Biosciences! You may apply for this position by sending your CV/resume to, referencing requisition number (GB21-288) in the subject line.